Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.15

+2.5%

Jan 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (6002)	3/22/2002 11:49:27 AM
From: JHP	Read Replies (1) of 52153

FOR IMMEDIATE RELEASE 3/8/2001 CHILDREN'S HOSPITAL AWARDED U.S. PATENT FOR METHODS OF INHIBITING ANGIOGENESIS VIA INCREASING IN VIVO CONCENTRATIONS OF ENDOSTATIN PROTEIN. Boston, Massachusettes, Children's Hospital Boston today announced that it has received U.S. Patent 6,174,861 for "Methods of Inhibiting Angiogenesis via Increasing In Vivo Concentrations of Endostatin Protein." The patent relates to an invention that may be used in the treatment of angiogenesis-dependent diseases such as cancer. The inventors are Michael S. O'Reilly and M. Judah Folkman. Children's Hospital is the nation's leading pediatric hospital and research facility. Research at Children's Hospital is conducted in affiliation with Harvard Medical School and the Howard Hughes Medical Institute. The Intellectual Property Office at Children's Hospital promotes the hospital's intellectual capital for public benefit through collaboration and partnership with industry. The IPO is committed to improving medicine for children and adults through these product development relationships. A listing of available technologies in the Children's Hospital portfolio can be found at childrenshospital.org.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next